Therapeutic blockade of activin-A improves NK cell function and antitumor immunity
- 27 August 2019
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 12 (596)
- https://doi.org/10.1126/scisignal.aat7527
Abstract
Natural killer (NK) cells are innate lymphocytes that play a major role in immunosurveillance against tumor initiation and metastatic spread. The signals and checkpoints that regulate NK cell fitness and function in the tumor microenvironment are not well defined. Transforming growth factor–β (TGF-β) is a suppressor of NK cells that inhibits interleukin-15 (IL-15)–dependent signaling events and increases the abundance of receptors that promote tissue residency. Here, we showed that NK cells express the type I activin receptor ALK4, which, upon binding to its ligand activin-A, phosphorylated SMAD2/3 to suppress IL-15–mediated NK cell metabolism. Activin-A impaired human and mouse NK cell proliferation and reduced the production of granzyme B to impair tumor killing. Similar to TGF-β, activin-A also induced SMAD2/3 phosphorylation and stimulated NK cells to increase their cell surface expression of several markers of ILC1 cells. Activin-A also induced these changes in TGF-β receptor–deficient NK cells, suggesting that activin-A and TGF-β stimulate independent pathways that drive SMAD2/3-mediated NK cell suppression. Last, inhibition of activin-A by follistatin substantially slowed orthotopic melanoma growth in mice. These data highlight the relevance of examining TGF-β–independent SMAD2/3 signaling mechanisms as a therapeutic axis to relieve NK cell suppression and promote antitumor immunity.Funding Information
- Cancer Research Institute
- Melanoma Research Alliance
- Harry J. Lloyd Charitable Trust
- National Health and Medical Research Council (#1124784, #1066770, #1057852, #1124907;)
- National Health and Medical Research Council (#1140406)
- National Health and Medical Research Council (#1088703)
- National Breast Cancer Foundation (PF-15-008)
- Cure Cancer Australia Foundation (#1124788)
This publication has 63 references indexed in Scilit:
- Myeloid TGF-β Responsiveness Promotes MetastasesCancer Discovery, 2013
- Innate lymphoid cells — a proposal for uniform nomenclatureNature Reviews Immunology, 2013
- TGF-β – an excellent servant but a bad masterJournal of Translational Medicine, 2012
- Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptorProceedings of the National Academy of Sciences of the United States of America, 2011
- Andromeda: A Peptide Search Engine Integrated into the MaxQuant EnvironmentJournal of Proteome Research, 2011
- Activin-A induces regulatory T cells that suppress T helper cell immune responses and protect from allergic airway diseaseThe Journal of Experimental Medicine, 2009
- MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantificationNature Biotechnology, 2008
- Exact Calculations of Average Power for the Benjamini-Hochberg ProcedureThe International Journal of Biostatistics, 2008
- Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTipsNature Protocols, 2007
- Interleukin 15–mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1Nature Immunology, 2007